NCI-60 explained

The NCI-60 cancer cell line panel is a group of 60 human cancer cell lines used by the National Cancer Institute (NCI) for the screening of compounds to detect potential anticancer activity.[1]

Purpose

The screening procedure is called the NCI-60 Human Tumor Cell Lines Screen, and it is one of the Discovery & Development Services of NCI's Developmental Therapeutics Program (DTP).[2] [3] [4] The screening rates for each cell line the cytostatic and cytotoxic impact of tested substances.

Due to the diversity of the cell lines, it is possible to compare tested compounds by their effect patterns, high correlation potentially corresponding to similar effect mechanisms.An automated comparison against a database of more than 88,000 pure compounds and more than 34,000 crude extracts is provided by the COMPARE tool, which shows a list of substances ranked by the Pearson correlation coefficients for a given test substance.[5]

The same panel is used in the Molecular Target Program for the characterization of molecular targets. Measurements include protein levels, RNA measurements, mutation status and enzyme activity levels.[6]

Cell Lines

The panel holds cell lines representing leukemia, melanoma, non-small-cell lung carcinoma, and cancers of the brain, ovary, breast, colon, kidney, and prostate.

13 additional cell lines are evaluated for use in the screening program,among them two lines deriving from so far not represented small-cell lung carcinoma.

All cell lines but one are available to other laboratories, including the additional cell lines.

Misidentification and Misclassification

Starting around the turn of the millennium, several cell lines were found to be misidentified or misclassified at the time of investigation or earlier:[7] [8] [9]

MDA-MB-435, originally classified as breast cancer cell line, was identified as being a melanoma cell line.When investigated further, current MDA-MB-435 appeared to be derived from the same individual as cell line M14.An examination of clones made clear that the mixup with M14 happened very early in the history of MDA-MB-435, before establishment in the Developmental Therapeutics Program.

NCI/ADR-RES, originally classified as breast cancer cell line, was identified as being an ovarian tumor cell line.NCI/ADR-RES appears to have been derived at some point in time from cell line OVCAR-8.Originally the cell line was named MCF-7/ADR-RES; it was renamed together with the change in classification.

Two brain cancer cell lines, SNB-19 and U251, were discovered to come from the same person.This makes a mixup likely.

A 61st cell line, MDA-N, has been confirmed to being derived from the misclassified MDA-MB-435 cell line.So it is also misclassified, really being a melanoma cell line, but the official website still lists it as breast cancer cell line.This cell line is not available .

The International Cell Line Authentication Committee maintains a list of contaminated cell lines.It includes the cell lines reported above, although usually with reporting dates and articles considerably later than the first dates and articles rising specific concern regarding the respective cell line.

Continued Use of Wrong Classification

Hundreds of research studies still use MDA-MB-435 as model of breast cancer, even after it was officially declared to be a melanoma cell line in 2007, and even in highest-rated international peer-reviewed journals.[10] Similar is true for other misidentified cell lines.

List of NCI-60 Cell Lines

The NCI-60 cell lines used by NCI's Human Tumor Cell Lines Screen as described on the website of the Developmental Therapeutics Program.[11] Links to corresponding Cellosaurus descriptions and Research Resource Identifiers (RRID) have been added.The Cellosaurus identifier is a combination of the cell line name variant chosen by Cellosaurus, with the Cellosaurus accession ID, the latter written as RRID.
Cell line Tumor classification (Potentially) misidentified Original classification Unavailable Doubling Time (Hours) Inoculation Density Cellosaurus identifier and link
CCRF-CEM 26.7 40000 CCRF-CEM (RRID:CVCL_0207)
Leukemia 28.6 40000 HL-60(TB) (RRID:CVCL_A794)
Leukemia 19.6 5000 K-562 (RRID:CVCL_0004)
MOLT-4 Leukemia 27.9 30000 MOLT-4 (RRID:CVCL_0013)
RPMI-8226 Leukemia 33.5 20000 RPMI-8226 (RRID:CVCL_0014)
SR-786 Leukemia 28.7 20000 SR (RRID:CVCL_1711)
22.9 7500 A-549 (RRID:CVCL_0023)
EKVX Non-Small Cell Lung 43.6 20000 EKVX (RRID:CVCL_1195)
HOP-62 Non-Small Cell Lung 39 10000 HOP-62 (RRID:CVCL_1285)
HOP-92 Non-Small Cell Lung 79.5 20000 HOP-92 (RRID:CVCL_1286)
NCI-H226 Non-Small Cell Lung 61 20000 NCI-H226 (RRID:CVCL_1544)
NCI-H23 Non-Small Cell Lung 33.4 20000 NCI-H23 (RRID:CVCL_1547)
NCI-H322M Non-Small Cell Lung 35.3 20000 NCI-H322M (RRID:CVCL_1557)
NCI-H460 Non-Small Cell Lung 17.8 7500 NCI-H460 (RRID:CVCL_0459)
NCI-H522 Non-Small Cell Lung 38.2 20000 NCI-H522 (RRID:CVCL_1567)
COLO 205 23.8 15000 COLO 205 (RRID:CVCL_0218)
HCC-2998 Colon 31.5 15000 HCC2998 (RRID:CVCL_1266)
Colon 17.4 5000 HCT 116 (RRID:CVCL_0291)
HCT-15 Colon 20.6 10000 HCT 15 (RRID:CVCL_0292)
Colon 19.5 5000 HT-29 (RRID:CVCL_0320)
KM12 Colon 23.7 15000 KM12 (RRID:CVCL_1331)
SW-620 Colon 20.4 10000 SW620 (RRID:CVCL_0547)
SF-268 33.1 15000 SF268 (RRID:CVCL_1689)
SF-295 CNS 29.5 10000 SF295 (RRID:CVCL_1690)
SF-539 CNS 35.4 15000 SF539 (RRID:CVCL_1691)
SNB-19 CNS yes CNS 34.6 15000 SNB-19 (RRID:CVCL_0535)
SNB-75 CNS 62.8 20000 SNB-75 (RRID:CVCL_1706)
U251 CNS yes CNS 23.8 7500 U-251MG (RRID:CVCL_0021)
LOX IMVI 20.5 7500 LOX-IMVI (RRID:CVCL_1381)
MALME-3M Melanoma 46.2 20000 Malme-3M (RRID:CVCL_1438)
M14 Melanoma 26.3 15000 M14 (RRID:CVCL_1395)
MDA-MB-435 Melanoma yes Breast 25.8 15000 MDA-MB-435 (RRID:CVCL_0417)
SK-MEL-2 Melanoma 45.5 20000 SK-MEL-2 (RRID:CVCL_0069)
SK-MEL-28 Melanoma 35.1 10000 SK-MEL-28 (RRID:CVCL_0526)
SK-MEL-5 Melanoma 25.2 10000 SK-MEL-5 (RRID:CVCL_0527)
UACC-257 Melanoma 38.5 20000 UACC-257 (RRID:CVCL_1779)
UACC-62 Melanoma 31.3 10000 UACC-62 (RRID:CVCL_1780)
IGROV-1 31 10000 IGROV-1 (RRID:CVCL_1304)
OVCAR-3 Ovarian 34.7 10000 OVCAR-3 (RRID:CVCL_0465)
OVCAR-4 Ovarian 41.4 15000 OVCAR-4 (RRID:CVCL_1627)
OVCAR-5 Ovarian 48.8 20000 OVCAR-5 (RRID:CVCL_1628)
OVCAR-8 Ovarian 26.1 10000 OVCAR-8 (RRID:CVCL_1629)
NCI/ADR-RES (originally MCF-7/ADR-RES)Ovarian yes Breast 34 15000 NCI-ADR-RES (RRID:CVCL_1452)
Ovarian 48.7 20000 SK-OV-3 (RRID:CVCL_0532)
786-O 22.4 10000 786-O (RRID:CVCL_1051)
A498 Renal 66.8 25000 A-498 (RRID:CVCL_1056)
ACHN Renal 27.5 10000 ACHN (RRID:CVCL_1067)
CAKI-1 Renal 39 10000 Caki-1 (RRID:CVCL_0234)
RXF 393 Renal 62.9 15000 RXF 393L (RRID:CVCL_1673)
SN12C Renal 29.5 15000 SN12C (RRID:CVCL_1705)
TK-10 Renal 51.3 15000 TK-10 (RRID:CVCL_1773)
UO-31 Renal 41.7 15000 UO-31 (RRID:CVCL_1911)
27.1 7500 PC-3 (RRID:CVCL_0035)
Prostate 32.3 10000 DU145 (RRID:CVCL_0105)
25.4 10000 MCF-7 (RRID:CVCL_0031)
Breast 41.9 20000 MDA-MB-231 (RRID:CVCL_0062)
MDA-MB-468Breast622000MDA-MB-468 (RRID:CVCL_0419)
HS 578TBreast53.820000Hs 578T (RRID:CVCL_0332)
MDA-N Melanoma yes Breast unavailable 22.5 15000 MDA-N (RRID:CVCL_1910)
Breast 53.9 20000 BT-549 (RRID:CVCL_1092)
Breast 45.5 20000 T-47D (RRID:CVCL_0553)

List of Additional Cell Lines

Additional cell lines evaluated for use in NCI's Tumor Cell Lines Screen as described on the website of the Developmental Therapeutics Program.Links to corresponding Cellosaurus descriptions and Research Resource Identifiers (RRID) have been added, as well as the species.[12]
Cell line Tumor classification Species Inoculation Density Cellosaurus identifier and link
LXFL 529 human 10000 LXFL 529L (RRID:CVCL_D085)
DMS 114 human 20000 DMS 114 (RRID:CVCL_1174)
SHP-77 Small Cell Lung human 40000 SHP-77 (RRID:CVCL_1693)
DLD-1 human 50000 DLD-1 (RRID:CVCL_0248)
KM20L2 Colon human 10000 KM20L2 (RRID:CVCL_D889)
SNB-78 human 20000 SNB-78 (RRID:CVCL_B321)
XF 498 CNS human 20000 XF 498 (RRID:CVCL_8928)
RPMI-7951 human 20000 RPMI-7951 (RRID:CVCL_1666)
M19-MEL Melanoma human 10000 M19-MEL (RRID:CVCL_B415)
RXF-631 human 10000 RXF 631L (RRID:CVCL_A780)
SN12K1 Renal human 10000 SN12K1 (RRID:CVCL_D106)
P388 mouse 50000 P388 (RRID:CVCL_7222)
P388/ADR Leukemia mouse 50000 P388/ADR (RRID:CVCL_IZ75)

Notes and References

  1. Web site: Cell Lines in the In Vitro Screen . 8 May 2015 . . . 6 January 2018.
  2. Web site: NCI-60 Human Tumor Cell Lines Screen . 26 August 2015 . . . 6 January 2018.
  3. Web site: Discovery & Development Services . 26 August 2015 . . . 6 January 2018.
  4. Web site: Welcome to the Developmental Therapeutics Program . . . 6 January 2018.
  5. Web site: COMPARE Analysis . 11 August 2015 . . . 6 January 2018.
  6. Web site: Molecular Targets . 12 May 2015 . . National Cancer Institute . 7 January 2018.
  7. Web site: MDA-MB-435, and its derivation MDA-N, are Melanoma cell lines, not breast cancer cell lines. . 8 May 2015 . . . 6 January 2018.
  8. Web site: Cell Line NCI/ADR-RES is an Ovarian tumor cell line, not a Breast line. . 8 May 2015 . . . 6 January 2018.
  9. Web site: CNS cell lines SNB-19 and U251 are derived from the same individual. . 8 May 2015 . . . 6 January 2018.
  10. Prasad. Vidudala VTS. Gopalan. Ramprasad OG. 2 June 2015. Continued use of MDA-MB-435, a melanoma cell line, as a model for human breast cancer, even in year, 2014. npj Breast Cancer. 1. 15002–. 10.1038/npjbcancer.2015.2. 28721362. 5515196.
  11. Web site: Cellosaurus search result: 61 hits for "NCI60 cancer cell line panel" . . . 7 January 2018. The reference includes the list of linked pages in the search result.
  12. Web site: Cellosaurus - a knowledge resource on cell lines . . . 17 January 2018. The reference includes the pages found by searching with the respective cell line names as given in the List of Additional Cell Lines.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "NCI-60".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.